



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/629,210	07/28/2003	Daniel G. Brady	27556	5311
7590	09/13/2007	Peter J. Gluck Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Ana, CA 92705	EXAMINER PREBILIC, PAUL B	
			ART UNIT 3738	PAPER NUMBER
			MAIL DATE 09/13/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/629,210	BRADY ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Paul B. Prebilic	3738	

All participants (applicant, applicant's representative, PTO personnel):

(1) Paul B. Prebilic. (3) \_\_\_\_\_

(2) David Weber. (4) \_\_\_\_\_

Date of Interview: 04 September 2007.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.

If Yes, brief description: Claims proposed for discussion were faxed to the examiner prior to the interview; see the attachment.

Claim(s) discussed: proposed claims 45, 54, 48, 52, and 55 of the draft claims.

Identification of prior art discussed: Lang as applied in the most recent Office action.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



**Paul B. Prebilic**  
Primary Examiner

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Weber queried whether the negative limitation precluding bifocal or multifocal lenses would avoid Lang explaining that Lang is directed to multifocal lenses. The Examiner explained that if Lang does not disclose monofocal lenses and only discloses multifocal lenses that such a limitation would overcome the rejection. The Examiner would have to thoroughly review Lang to make an independent determination of this. Mr. Weber discussed claim 48 as to the blazed profile on a planar surface. The Examiner thought that if the prior art such as Cohen knew how to do the same, it would have been *prima facie* obvious to do the same for the Lang diffractive optic. Mr. Weber explained that he would file an amendment based upon the interview.

DRAFT

SEP. 4. 2007 12:28PM

ADVNC. MED. OPTICS INC

NO. 6412 P. 1

Application Number: 10/629,210  
Art Unit: 3738



**LEGAL DEPARTMENT**

**1700 E. St. Andrew Place, Santa Ana, CA 92705**

**Tel. (714) 247-8200 – Fax (714) 247-8679**

**FAX COVER SHEET**

**CONFIDENTIAL / ATTORNEY CLIENT PRIVILEGED COMMUNICATION**

**DATE: September 4, 2007**

**NO. OF PAGES (WITH THIS COVER): 5**

	<b>NAME</b>	<b>FAX NO.</b>	<b>PHONE NO.</b>
<b>RECIPIENT:</b>	Patent Examiner Paul B. Prebilic	571-273-4758	571-272-4758

**FROM:** David Weber, Patent Agent (714.274.8232)

**SUBJECT:** U.S. Patent Application 10/629,210

**MESSAGE:** Attached are pages of the claims to be discussed during our phone interview for September 4, 2007 at 4:00 pm EDT.

**ORIGINAL WILL NOT FOLLOW**

**CONFIDENTIALITY NOTE:** The information contained in this facsimile message is privileged or confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is neither allowed nor intended. If you have received this communication in error, please immediately notify us by telephone at the below number, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

If there is a problem with the transmission of this message, please call Becky Smith (714) 247-8516.

DRAFT

SEP. 4. 2007 12:28PM

ADVNC. MED. OPTICS INC

NO. 6412 P. 2

Application Number: 10/629,210  
Art Unit: 3738

**DRAFT VERSION OF AMENDMENTS TO THE CLAIMS**

45. (Currently Amended) An intraocular lens for insertion into an eye, comprising:

a primary intraocular lens having vision correcting power when placed into an eye of a patient; and

a supplemental intraocular lens that modifies the vision correcting power of the primary intraocular lens when in the eye and that comprises a substantially completely diffractive optic that does not provide bifocal or multifocal vision correction, the optic being disposed separately from the primary intraocular lens, the supplemental intraocular lens being positively powered or negatively powered, depending on whether the vision correcting power is insufficient or excessive, respectively.

53. (New) The intraocular lens according to claim 45, wherein the diffractive optic is made of a material having a refractive index, the power of the supplemental intraocular lens is independent of a refractive index of the material.

54. (New) The intraocular lens according to claim 45, wherein the primary intraocular lens and the supplemental intraocular lens are attached to one another.

48. (Previously Presented) An intraocular lens for insertion into an eye, comprising:

a primary intraocular lens having vision correcting power when in an eye of a patient; and

a supplemental intraocular lens that modifies the vision correcting power of the primary intraocular lens when in the eye and that comprises a blazed profile *on a planar substrate*, the supplemental intraocular lens being disposed separately from the primary intraocular lens, the supplemental intraocular lens comprising a substantially completely diffractive optic having a positive optical power or a negative optical power.

52. (New) The intraocular lens according to claim 48, wherein the supplemental intraocular lens does not provide multifocal or bifocal vision correction.

55. (New) An intraocular lens for insertion into an eye, comprising:

a primary intraocular lens having vision correcting power when placed into an eye of a patient; and

a supplemental intraocular lens that modifies the vision correcting power of the primary intraocular lens when in the eye and that comprises a diffractive optic providing only monofocal vision correction, the optic being disposed separately from the primary intraocular lens.